查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1718069

按檢測類型、癌症類型、技術、付款來源、應用程式和最終用戶分類的多癌症篩檢市場—2025 年至 2030 年全球預測

Multicancer Screening Market by Test Type, Cancer Type, Technology, Payment Source, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計多癌篩檢市場規模在 2024 年將達到 15.3 億美元，在 2025 年將達到 16.7 億美元，在 2030 年將達到 27.2 億美元，複合年成長率為 10.05%。

主要市場統計數據
基準年2024年 15.3億美元
預計2025年 16.7億美元
預測年份 2030 27.2億美元
複合年成長率（%） 10.05%

近年來，醫療保健領域在癌症早期發現和管理方面取得了重大進展。多重癌症篩檢是基因組學、診斷學和臨床研究交叉領域的一個快速成長的領域，它正在改變臨床醫生進行癌症檢測的方式。這項新模式旨在利用先進技術和綜合診斷平台來更全面地了解潛在的惡性腫瘤。

越來越多的研究支持早期診斷、風險評估和個人化治療策略，推動了多癌症篩檢的發展。該領域的創新者不斷篩檢通訊協定，以提高準確性並減少假陽性。因此，患者將受益於更個人化和及時的干涉，從而改善整體治療效果。

先驅研究和臨床檢驗強調了準確的分子分析和多種診斷測試整合的重要性。這些進步不僅增強了臨床決策能力，而且為侵入性較小、可高度預測癌症存在的診斷篩檢方法鋪平了道路。繼續重視早期發現將有助於提高存活率和更有效地分配醫療資源，標誌著精準醫療過程中的重要里程碑。

重新定義多癌症篩檢的變革性轉變

該領域最近的轉型變化從根本上重新定義了行業標準和市場動態。下一代定序、質譜和聚合酵素鏈鎖反應等技術突破將診斷準確性推向了新的高度。除了這些進步之外，人們越來越依賴實驗室開發的測試和液態切片技術，這些技術正在改變臨床醫生檢測和監測癌症生物標記的方式。

篩檢技術的進步與醫療保健重點向早期發現和預防保健的廣泛轉變相輔相成。目前，重點是開發能夠在低豐度生物標記場景中實現快速週轉時間和高靈敏度的平台。此外，新的遺傳和分子生物分析的整合促進了對癌症異質性的更細緻的理解。這將導致更精確的風險分層，這在考慮不同癌症類型及其相應治療方案之間的複雜相互作用時至關重要。

隨著情勢的不斷變化，相關人員越來越意識到利用這些創新所需的策略必要事項。顯然，對尖端診斷工具和綜合篩檢通訊協定的投資不僅使臨床實踐現代化，而且還有助於實現強調早期療育而非傳統反應策略的模式轉移。

多癌症篩檢市場的關鍵細分洞察

對多癌症篩檢市場的全面分析揭示了多方面的細分見解，這對於理解當前的行業動態至關重要。按測試類型細分包括對基因組、實驗室開發的測試和液態切片的嚴格評估。這些診斷方法為癌症檢測提供了多種方法，每種方法都利用獨特的生物標記和技術細節來幫助制定早期療育策略。研發和產業專家指出，基因組提供了識別易感性和突變所必需的基因藍圖，實驗室開發的測試允許進行客製化評估和實驗室定義的參數，液態切片具有微創性並可快速獲得結果。

以癌症類型分類，檢查的癌症包括乳癌、大腸癌、白血病、肺癌、特異性多器官癌和攝護腺癌。癌症類型的多樣性需要徹底了解其各自的生物機制和診斷挑戰。此外，按技術細分顯示，已經引入了質譜、微陣列、次世代定序和聚合酵素鏈鎖反應等各種平台，每個平台都在精確地推進這一領域的發展。這些技術提供了不同的方法來量化生物標記和了解基因圖譜，有助於客製化治療方法。

市場也根據付款來源進行細分，透過支付來源評估診斷解決方案，包括政府補貼、自付、私人健康保險等。這種細分凸顯了影響市場採用和可近性的經濟和政策影響。診斷篩檢分為早期發現和風險評估，預後預測分為病患監測、治療選擇和治療效果評估。在研究應用領域，專注於生物標記發現和基因研究的子區隔正在成為持續創新的催化劑。最後，最終用戶細分包括門診手術中心、診斷中心、醫院、研究機構和專科診所，突顯了多癌症篩檢技術在不同醫療保健環境中的廣泛部署。

這些細分洞察提供了對市場促進因素和障礙的詳細了解，幫助相關人員根據影響當前格局的各種診斷、技術和經濟因素做出明智的決策。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 癌症發生率上升和人口老化
      • 醫療成本上漲和政府舉措
      • 早期檢測對於改善患者預後越來越重要
    • 限制因素
      • 多重癌症篩檢高成本
    • 機會
      • 非侵入性和微創篩檢程序的開發
      • 巨量資料與數位健康平台的整合
    • 任務
      • 解決對足夠安全性和有效性的擔憂
  • 市場區隔分析
    • 測試類型：液態生物檢體因其患者友善的樣本採集過程而越來越受到青睞
    • 用途：擴大多癌種篩檢在預測的應用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

6. 多癌種篩檢市場（依檢測類型）

  • 介紹
  • 基因面板
  • 臨床開發測試
  • 液態生物檢體

7. 多重癌種篩檢市場

  • 介紹
  • 乳癌
  • 大腸直腸癌
  • 白血病
  • 肺癌
  • 特異性多重器官癌症
  • 攝護腺癌

8. 多重癌種篩檢市場（依技術）

  • 介紹
  • 質譜法
  • 微陣列
  • 下一代定序
  • 聚合酵素鏈鎖反應

第9章 多癌種篩檢市場（依付款來源）

  • 介紹
  • 政府補貼
  • 自費
  • 私人健康保險

第 10 章 多癌種篩檢市場（依應用）

  • 介紹
  • 診斷篩檢
    • 早期檢測
    • 風險評估
  • 預後
    • 病患監測
    • 治療方法方案
    • 治療效果評估
  • 研究用途
    • 生物標記發現
    • 基因研究

第 11 章 多癌種篩檢市場（依最終使用者）

  • 介紹
  • 門診手術中心
  • 診斷中心
  • 醫院
  • 研究所
  • 專科診所

12. 美洲多癌篩檢市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

13. 亞太地區多癌症種篩檢市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

14. 歐洲、中東和非洲多癌篩檢市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • ANPAC Bio-Medical Science Co., Ltd.
  • Burning Rock BIoTech Limited
  • Caris Life Sciences
  • Coyne Medical Ltd.
  • Delfi Diagnostics, Inc.
  • Elypta AB
  • EpiCypher, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Foundation Medicine, Inc.
  • Freenome Holdings, Inc.
  • Fulgent Genetics, Inc.
  • Gene Solutions
  • Grail, LLC by Illumina, Inc.
  • Guangzhou AnchorDx Medical Co., Ltd.
  • Guardant Health, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • Micronoma, Inc.
  • MiRXES Pte Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Naveris, Inc.
  • NeoGenomics Laboratories
  • OneTest
  • Siemens Healthineers AG
  • StageZero Life Sciences. Ltd.
Product Code: MRR-5C6F41F5AFE7

The Multicancer Screening Market was valued at USD 1.53 billion in 2024 and is projected to grow to USD 1.67 billion in 2025, with a CAGR of 10.05%, reaching USD 2.72 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.53 billion
Estimated Year [2025] USD 1.67 billion
Forecast Year [2030] USD 2.72 billion
CAGR (%) 10.05%

In recent years, the healthcare arena has witnessed a significant evolution in the early detection and management of cancers. Multicancer screening, a burgeoning field at the intersection of genomics, diagnostics, and clinical research, is transforming the way clinicians approach cancer detection. This emerging paradigm seeks to offer more comprehensive insights into potential malignancies by leveraging advanced technologies and integrative diagnostic platforms.

The evolution of multicancer screening is driven by a growing body of research that supports early diagnosis, risk assessment, and tailored treatment strategies. Innovators in the field are continuously refining screening protocols to improve accuracy and reduce false positives. As a result, patients benefit from more personalized and timely interventions, which in turn enhance overall treatment outcomes.

Pioneering studies and clinical validations have underscored the importance of precise molecular profiling and the integration of multiple diagnostic tests. These advancements not only augment clinical decision-making but also pave the way for diagnostic screening methods that are both less invasive and highly predictive of cancer presence. The continued emphasis on early detection contributes to improved survival rates and a more efficient allocation of healthcare resources, marking a critical milestone in the journey toward precision medicine.

Transformative Shifts Redefining the Multicancer Screening Landscape

Recent transformative shifts within the field have fundamentally redefined industry standards and market dynamics. Technological breakthroughs such as next-generation sequencing, mass spectrometry, and polymerase chain reaction have propelled diagnostic accuracy to new heights. These advancements are complemented by a growing reliance on laboratory developed tests and liquid biopsy techniques that are changing the way clinicians detect and monitor cancer biomarkers.

The evolution in screening technologies is closely linked with a broader shift in healthcare priorities toward early detection and preventive care. Emphasis is now placed on developing platforms that allow for rapid turnaround times and higher sensitivity in low-volume biomarker scenarios. Furthermore, integration of novel genetic and molecular analyses has facilitated a more nuanced understanding of cancer heterogeneity. This, in turn, enables more accurate risk stratification, which is vital when considering the complex interplay between various cancer types and corresponding treatment options.

As the landscape continues to adapt, stakeholders are increasingly aware of the strategic imperatives required to harness these innovations. It is clear that investments in state-of-the-art diagnostic tools and comprehensive screening protocols are not only modernizing clinical practices but are also contributing to a paradigm shift that emphasizes early intervention over conventional reactive strategies.

Key Segmentation Insights in the Multicancer Screening Market

A comprehensive analysis of the multicancer screening market reveals multifaceted segmentation insights central to understanding current industry dynamics. The segmentation based on test type includes a rigorous evaluation of gene panels, laboratory developed tests, and liquid biopsies. These diagnostic modalities offer diverse approaches to cancer detection, each leveraging unique biomarkers and technological nuances to support early intervention strategies. Researchers and industry experts note that gene panels provide a genetic roadmap that is essential for identifying predispositions and mutations, while laboratory developed tests allow for tailored assessments and laboratory-defined parameters, and liquid biopsies minimize invasiveness with rapid results.

When segmented by cancer type, the market research scrutinizes an array of cancers including breast, colorectal, leukemia, lung, non-specific multi-organ cancers, and prostate cancer. The diversity within cancer types necessitates a robust understanding of the biological mechanisms at play and the variable diagnostic challenges associated with each category. Furthermore, segmentation based on technology introduces a spectrum of platforms such as mass spectrometry, microarray, next-generation sequencing, and polymerase chain reaction, each advancing the field with precision. These technologies offer different approaches to quantifying biomarkers and understanding genetic profiles, which aids in tailoring treatment regimens.

The market is also segmented by payment source where diagnostic solutions are evaluated within frameworks that include government subsidies, out-of-pocket payments, and private health insurance. This segmentation underscores the economic and policy influences governing market adoption and accessibility. Additionally, segmentation by application brings forth insights under diagnostic screening, prognostics, and research applications, with diagnostic screening further differentiated by early detection and risk assessment, and prognostics divided into patient monitoring, therapy selection, and treatment efficacy assessment. Within the realm of research applications, sub-segmentations focus on biomarker discovery and genetic research, thereby serving as a catalyst for continuous innovation. Lastly, categorization based on the end user includes ambulatory surgical centers, diagnostic centers, hospitals, research institutions, and specialty clinics, highlighting the broad deployment of multicancer screening technologies across diverse healthcare settings.

Together, these segmentation insights provide a detailed understanding of market drivers and barriers, empowering stakeholders to make informed decisions based on varying diagnostic, technological, and economic factors that shape the current landscape.

Based on Test Type, market is studied across Gene Panel, Laboratory Developed Test, and Liquid Biopsy.

Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Non-Specific Multi-Organ Cancer, and Prostate Cancer.

Based on Technology, market is studied across Mass Spectrometry, Microarray, Next - Generation Sequencing, and Polymerase Chain Reaction.

Based on Payment Source, market is studied across Government Subsidies, Out-of-Pocket Payment, and Private Health Insurance.

Based on Application, market is studied across Diagnostic Screening, Prognostics, and Research Applications. The Diagnostic Screening is further studied across Early Detection and Risk Assessment. The Prognostics is further studied across Patient Monitoring, Therapy Selection, and Treatment Efficacy Assessment. The Research Applications is further studied across Biomarker Discovery and Genetic Research.

Based on End User, market is studied across Ambulatory Surgical Centers, Diagnostic Centers, Hospitals, Research Institutions, and Specialty Clinics.

Regional Insights Shaping the Global Multicancer Screening Market

Regional dynamics play a crucial role in steering the multicancer screening market, with distinct trends emerging across various geographies. In the Americas, increased funding for research, supportive regulatory frameworks, and a strong emphasis on early detection have collectively accelerated the adoption of advanced screening technologies. An ecosystem enriched by academic collaborations and public-private partnerships is fostering the rapid integration of these diagnostics into routine clinical practice.

Across Europe, the Middle East, and Africa, the landscape is simultaneously evolving with an emphasis on harmonized healthcare practices and large-scale government interventions targeted at disease prevention. The region has seen a progressive push towards the implementation of precision screening, driven by both rising cancer incidences and increasing awareness regarding early diagnosis. Meanwhile, the Asia-Pacific region has emerged as an influential player, characterized by rapid economic growth, technological advancements, and broad patient accessibility. Investment in state-of-the-art diagnostic centers and the ongoing integration of innovative testing methodologies are establishing a robust market presence that is poised for sustainable growth.

Collectively, these regional insights emphasize the global nature of the market and highlight the varying pace at which different regions are adapting to and adopting the transformative potential of multicancer screening technologies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Driving Innovation in Multicancer Screening

The multicancer screening market is marked by the active participation of several trailblazing companies whose innovations drive the industry's momentum. Noteworthy players such as ANPAC Bio-Medical Science Co., Ltd. and Burning Rock Biotech Limited have carved out critical niches by offering advanced diagnostic tests and comprehensive genomic analyses. Organizations like Caris Life Sciences and Coyne Medical Ltd. have significantly influenced cancer diagnostics by integrating cutting-edge bioinformatics with traditional laboratory operations.

Other key industry leaders, including Delfi Diagnostics, Inc. and Elypta AB, are leveraging novel molecular profiling techniques to enhance early detection and risk assessment capabilities. EpiCypher, Inc., Epigenomics AG, and Exact Sciences Corporation have also played pivotal roles by further refining the accuracy of diagnostic platforms while expanding the scope of genetic screening. Foundation Medicine, Inc., Freenome Holdings, Inc., and Fulgent Genetics, Inc. have introduced innovative testing protocols that incorporate multi-dimensional data analysis and refined patient stratification. Companies such as Gene Solutions and Grail, LLC by Illumina, Inc. have demonstrated expertise in combining robust research with clinical applications.

Further contributions from Guangzhou AnchorDx Medical Co., Ltd., Guardant Health, Inc., Invitae Corporation, and Laboratory Corporation of America Holdings underscore an industry-wide commitment to precision and efficiency. In addition, Lucence Health Inc., Micronoma, Inc., MiRXES Pte Ltd., and Myriad Genetics, Inc. have set benchmarks for integrating streamlined diagnostics with next-generation treatment selections. The market continues to benefit from the diverse contributions of Natera, Inc., Naveris, Inc., NeoGenomics Laboratories, OneTest, Siemens Healthineers AG, and StageZero Life Sciences. Their collective expertise fosters a competitive environment that fuels ongoing advancements in early cancer screening and personalized medicine applications.

The report delves into recent significant developments in the Multicancer Screening Market, highlighting leading vendors and their innovative profiles. These include ANPAC Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Caris Life Sciences, Coyne Medical Ltd., Delfi Diagnostics, Inc., Elypta AB, EpiCypher, Inc., Epigenomics AG, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Fulgent Genetics, Inc., Gene Solutions, Grail, LLC by Illumina, Inc., Guangzhou AnchorDx Medical Co., Ltd., Guardant Health, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Lucence Health Inc., Micronoma, Inc., MiRXES Pte Ltd., Myriad Genetics, Inc., Natera, Inc., Naveris, Inc., NeoGenomics Laboratories, OneTest, Siemens Healthineers AG, and StageZero Life Sciences. Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to drive further innovation by investing in research and development that spans the full spectrum of diagnostic modalities. It is advisable to enhance collaborations between clinical research institutions and diagnostic companies to accelerate the translation of novel biomarkers into clinically actionable tools. Strategic investments in technologies such as next-generation sequencing, mass spectrometry, and polymerase chain reaction will provide the robust framework required for developing more precise screening solutions.

Stakeholders should also consider leveraging real-world evidence and comprehensive market segmentation data when tailoring product offerings to the evolving needs of diverse patient populations. Engaging with regulatory bodies to streamline approval processes and actively participating in public health initiatives can foster a more supportive environment for rapid adoption and scaling of multicancer screening programs. The effective integration of digital health tools and real-time data analytics into diagnostic platforms is another pertinent recommendation that can improve patient monitoring and treatment efficacy assessments. Overall, a proactive approach backed by agile decision-making and strategic foresight is essential to stay ahead in this competitive and ever-evolving market.

Conclusion: Embracing Innovation and Precision in Cancer Screening

In summary, the multicancer screening market reflects a transformative period marked by rapid technological advancements and sophisticated segmentation models. Detailed analysis across diverse diagnostic methods, cancer types, and technological applications reveals an industry that is not only dynamic but also deeply committed to early and precise detection. The global regional insights further emphasize the necessity of customized approaches tailored to specific market dynamics, while leading company innovations set the stage for further breakthroughs. The ongoing focus on precision medicine underlines the importance of continuous research and collaborative efforts, ensuring that advancements in diagnostic tools translate into improved patient outcomes and enhanced clinical practices.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer disease and rising aging population
      • 5.1.1.2. Rise in healthcare expenditure and government initiative
      • 5.1.1.3. Growing emphasis on early detection for improved patient outcomes
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with multicancer screening
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of non-invasive and minimally invasive screening procedures
      • 5.1.3.2. Integration of big data and digital health platforms
    • 5.1.4. Challenges
      • 5.1.4.1. Addressing concerns associated with adequate safety and efficacy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Test Type: Increasing preference for liquid biopsy due to its patient-friendly sample collection process
    • 5.2.2. Application: Expanding application of multicancer screening in prognostics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Multicancer Screening Market, by Test Type

  • 6.1. Introduction
  • 6.2. Gene Panel
  • 6.3. Laboratory Developed Test
  • 6.4. Liquid Biopsy

7. Multicancer Screening Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Colorectal Cancer
  • 7.4. Leukemia
  • 7.5. Lung Cancer
  • 7.6. Non-Specific Multi-Organ Cancer
  • 7.7. Prostate Cancer

8. Multicancer Screening Market, by Technology

  • 8.1. Introduction
  • 8.2. Mass Spectrometry
  • 8.3. Microarray
  • 8.4. Next - Generation Sequencing
  • 8.5. Polymerase Chain Reaction

9. Multicancer Screening Market, by Payment Source

  • 9.1. Introduction
  • 9.2. Government Subsidies
  • 9.3. Out-of-Pocket Payment
  • 9.4. Private Health Insurance

10. Multicancer Screening Market, by Application

  • 10.1. Introduction
  • 10.2. Diagnostic Screening
    • 10.2.1. Early Detection
    • 10.2.2. Risk Assessment
  • 10.3. Prognostics
    • 10.3.1. Patient Monitoring
    • 10.3.2. Therapy Selection
    • 10.3.3. Treatment Efficacy Assessment
  • 10.4. Research Applications
    • 10.4.1. Biomarker Discovery
    • 10.4.2. Genetic Research

11. Multicancer Screening Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Diagnostic Centers
  • 11.4. Hospitals
  • 11.5. Research Institutions
  • 11.6. Specialty Clinics

12. Americas Multicancer Screening Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Multicancer Screening Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Multicancer Screening Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Function Health partners with GRAIL to expand Galleri multi-cancer early detection test access
    • 15.3.2. Lucence and DxD Hub partner to enhance multi-cancer detection through alternative sample testing
    • 15.3.3. Freenome secures USD 254 million funding to advance multi-cancer blood tests and drive early detection innovations
    • 15.3.4. PanGIA Biotech Advances Multi-Cancer Detection with Liquid Biopsy Platform
    • 15.3.5. Introduction of Riskguard, A Hereditary Cancer Screening Test by Exact Sciences Corp
    • 15.3.6. Strategic Partnership Between SeekIn Inc. and Oncolnv to Enhance Global Cancer Detection Efforts
    • 15.3.7. Collaboration Between AnchorDx and DiaCarta to Revolutionize Global Cancer Screening
    • 15.3.8. Burning Rock Biotech Achieves Global Recognition with OverC Multi-Cancer Detection Blood Test
    • 15.3.9. Elypta Attains ISO 13485:2016 Certification, Advancing GAGome-Based Multicancer Detection
    • 15.3.10. Strategic Acquisition by Freenome Amplifies Cancer Screening Capabilities through Oncimmune Ltd's Advanced Diagnostics
    • 15.3.11. Lucence Advances Cancer Detection with Innovative MCED Blood Test: A Strategic Unveiling in the U.S.
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ANPAC Bio-Medical Science Co., Ltd.
  • 2. Burning Rock Biotech Limited
  • 3. Caris Life Sciences
  • 4. Coyne Medical Ltd.
  • 5. Delfi Diagnostics, Inc.
  • 6. Elypta AB
  • 7. EpiCypher, Inc.
  • 8. Epigenomics AG
  • 9. Exact Sciences Corporation
  • 10. Foundation Medicine, Inc.
  • 11. Freenome Holdings, Inc.
  • 12. Fulgent Genetics, Inc.
  • 13. Gene Solutions
  • 14. Grail, LLC by Illumina, Inc.
  • 15. Guangzhou AnchorDx Medical Co., Ltd.
  • 16. Guardant Health, Inc.
  • 17. Invitae Corporation
  • 18. Laboratory Corporation of America Holdings
  • 19. Lucence Health Inc.
  • 20. Micronoma, Inc.
  • 21. MiRXES Pte Ltd.
  • 22. Myriad Genetics, Inc.
  • 23. Natera, Inc.
  • 24. Naveris, Inc.
  • 25. NeoGenomics Laboratories
  • 26. OneTest
  • 27. Siemens Healthineers AG
  • 28. StageZero Life Sciences. Ltd.

LIST OF FIGURES

  • FIGURE 1. MULTICANCER SCREENING MARKET MULTI-CURRENCY
  • FIGURE 2. MULTICANCER SCREENING MARKET MULTI-LANGUAGE
  • FIGURE 3. MULTICANCER SCREENING MARKET RESEARCH PROCESS
  • FIGURE 4. MULTICANCER SCREENING MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MULTICANCER SCREENING MARKET DYNAMICS
  • TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 174. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 182. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 183. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 192. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 193. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 200. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 201. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 202. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 209. THAILAND MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 210. THAILAND MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 211. THAILAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 218. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 219. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 237. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 238. DENMARK MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 239. DENMARK MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 246. EGYPT MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 247. EGYPT MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 248. EGYPT MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 255. FINLAND MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 256. FINLAND MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 257. FINLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 264. FRANCE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 265. FRANCE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 266. FRANCE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 273. GERMANY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 274. GERMANY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. GERMANY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 282. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 283. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 290. ITALY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 291. ITALY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 292. ITALY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 293. ITALY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 298. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 299. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 300. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 301. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 302. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 307. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 308. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 309. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 310. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 311. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 316. NORWAY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 317. NORWAY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 318. NORWAY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 319. NORWAY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 320. NORWAY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 325. POLAND MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 326. POLAND MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 327. POLAND MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 328. POLAND MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 329. POLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. QATAR MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 333. QATAR MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 334. QATAR MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 335. QATAR MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 336. QATAR MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 337. QATAR MULTICANCER SCREENING MARKET SIZE, B